By Daniella Parra
ReAlta Life Sciences’ Pegtarazimod demonstrated significant clinical improvement and reduction in inflammatory markers in patients with lower gastrointestinal aGvHD, the company said.
Clinical MAGIC stage improvement observed for 6 of 6 patients with steroid-refractory aGvHD, with 4 of 5 participants demonstrating lower GI MAGIC Stage improvement of 1, 2, or 3 stages over 7 days of treatment, they said.
“Pegtarazimod treatment shows compelling clinical improvements for patients with steroid-refractory aGvHD, particularly in lower gastrointestinal involvement,” said Robert Zeiser, M.D., from the Medical Center, University of Freiburg and lead author of the study. “The statistically significant decrease in plasma myeloperoxidase levels suggests a direct pathway to reducing tissue damage and potentially improving outcomes for patients with this life-threatening condition.”
READ MORE
NYSE Firesides Scheduled Dec 9, 2025 & Feb 3, 2026
Never Miss our Weekly Highlights HERE
